{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:38:56Z","timestamp":1789839536870,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41401-020-0395-5","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T08:03:39Z","timestamp":1587024219000},"page":"1609-1620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells"],"prefix":"10.1038","volume":"41","author":[{"given":"Xu","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-ru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KeWei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"395_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","volume":"157","author":"F Kanwal","year":"2019","unstructured":"Kanwal F, Singal AG. Surveillance for HCC: current best practice and future direction. Gastroenterology. 2019;157:54\u201364.","journal-title":"Gastroenterology"},{"key":"395_CR2","doi-asserted-by":"crossref","unstructured":"Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017;11:389\u201398.","DOI":"10.5582\/bst.2017.01202"},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5582\/bst.2018.01239","volume":"12","author":"Z Sun","year":"2018","unstructured":"Sun Z, Zhu Y, Aminbuhe, Fan Q, Peng J, Zhang N. Differential expression of APE1 in hepatocellular carcinoma and the effects on proliferation and apoptosis of cancer cells. Biosci Trends. 2018;12:456\u201362.","journal-title":"Biosci Trends"},{"key":"395_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2015.08.009","volume":"379","author":"X Yan","year":"2016","unstructured":"Yan X, Qiu Y. Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett. 2016;379:220\u20134.","journal-title":"Cancer Lett"},{"key":"395_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5582\/ddt.2017.01036","volume":"11","author":"J Gao","year":"2017","unstructured":"Gao J, Song P. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: expectation. Drug Disco Ther. 2017;11:168\u20139.","journal-title":"Drug Disco Ther"},{"key":"395_CR6","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","volume":"23","author":"D Dimitroulis","year":"2017","unstructured":"Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23:5282\u201394.","journal-title":"World J Gastroenterol"},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5582\/bst.2018.01082","volume":"12","author":"F Qi","year":"2018","unstructured":"Qi F, Wang J, Zhao L, Cai P, Tang W, Wang Z. Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met\/ERK signaling pathway. Biosci Trends. 2018;12:291\u20137.","journal-title":"Biosci Trends"},{"key":"395_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"395_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5582\/bst.2018.01246","volume":"12","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends. 2019;12:537\u201352.","journal-title":"Biosci Trends"},{"key":"395_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cid\/ciz206","volume":"70","author":"N Elket","year":"2020","unstructured":"Elket N, Kendjo E, Thellier M, Assoumou L, Potard V, Taieb A, et al. Propensity score analysis of artesunate versus quinine for severe imported Plasmodium falciparum malaria in France. Clin Infect Dis. 2020;70:280\u20137.","journal-title":"Clin Infect Dis"},{"key":"395_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ebiom.2014.11.010","volume":"2","author":"S Krishna","year":"2015","unstructured":"Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, et al. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine. 2015;2:82\u201390.","journal-title":"EBioMedicine"},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-018-0561-0","volume":"11","author":"TK Vatsveen","year":"2018","unstructured":"Vatsveen TK, Myhre MR, Steen CB, Walchli S, Lingjaerde OC, Bai B, et al. Artesunate shows potent anti-tumor activity in B-cell lymphoma. J Hematol Oncol. 2018;11:23.","journal-title":"J Hematol Oncol"},{"key":"395_CR14","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/med.21580","volume":"39","author":"X Sun","year":"2019","unstructured":"Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, et al. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019;39:2172\u201393.","journal-title":"Med Res Rev"},{"key":"395_CR15","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.2174\/1568026616666160212122820","volume":"16","author":"M Ilamathi","year":"2016","unstructured":"Ilamathi M, Santhosh S, Sivaramakrishnan V. Artesunate as an anti-cancer agent targets Stat-3 and favorably suppresses hepatocellular carcinoma. Curr Top Med Chem. 2016;16:2453\u201363.","journal-title":"Curr Top Med Chem"},{"key":"395_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MEG.0000000000000066","volume":"26","author":"YP Vandewynckel","year":"2014","unstructured":"Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, et al. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014;26:861\u201370.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"395_CR17","unstructured":"ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=artesunate&cntry=&state=&city=&dist= (2019)."},{"key":"395_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"395_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.yexmp.2019.01.006","volume":"107","author":"AL Greenshields","year":"2019","unstructured":"Greenshields AL, Fernando W, Hoskin DW. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 2019;107:10\u201322.","journal-title":"Exp Mol Pathol"},{"key":"395_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/aps.2017.156","volume":"39","author":"SS Zhang","year":"2018","unstructured":"Zhang SS, Ni YH, Zhao CR, Qiao Z, Yu HX, Wang LY, et al. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. Acta Pharmacol Sin. 2018;39:438\u201348.","journal-title":"Acta Pharmacol Sin"},{"key":"395_CR21","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"395_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12328-016-0670-7","volume":"9","author":"M Moriguchi","year":"2016","unstructured":"Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2016;9:184\u201390.","journal-title":"Clin J Gastroenterol"},{"key":"395_CR23","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293\u2013300.","journal-title":"J Clin Oncol"},{"key":"395_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jhep.2011.01.047","volume":"55","author":"WT Tai","year":"2011","unstructured":"Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol. 2011;55:1041\u20138.","journal-title":"J Hepatol"},{"key":"395_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-230X-3-19","volume":"3","author":"H Huynh","year":"2003","unstructured":"Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.","journal-title":"BMC Gastroenterol"},{"key":"395_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccr.2009.12.048","volume":"17","author":"G He","year":"2010","unstructured":"He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKbeta\/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17:286\u201397.","journal-title":"Cancer Cell"},{"key":"395_CR27","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.3390\/molecules15042886","volume":"15","author":"S Sertel","year":"2010","unstructured":"Sertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T. Pharmacogenomic identification of c-Myc\/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules. 2010;15:2886\u2013910.","journal-title":"Molecules"},{"key":"395_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13659-018-0162-1","volume":"8","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xu G, Zhang S, Wang D, Saravana Prabha P, Zuo Z. Antitumor research on artemisinin and its bioactive derivatives. Nat Prod Bioprospect. 2018;8:303\u201319.","journal-title":"Nat Prod Bioprospect"},{"key":"395_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1083\/jcb.201102095","volume":"194","author":"T Finkel","year":"2011","unstructured":"Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194:7\u201315.","journal-title":"J Cell Biol"},{"key":"395_CR30","doi-asserted-by":"publisher","unstructured":"Khan AI, Kapoor A, Che J, Martin L, Rogazzo M, Mercier T, et al. The anti-malarial drug artesunate attenuates cardiac injury in a rodent model of myocardial infarction. Shock 2017. https:\/\/doi.org\/10.1097\/SHK.0000000000000963.","DOI":"10.1097\/SHK.0000000000000963"},{"key":"395_CR31","doi-asserted-by":"crossref","unstructured":"Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453\u201362.","DOI":"10.1016\/j.cub.2014.03.034"},{"key":"395_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tiv.2018.06.008","volume":"52","author":"J Kundu","year":"2018","unstructured":"Kundu J, Kim DH, Chae IG, Lee JK, Lee S, Jeong CH, et al. Silicon dioxide nanoparticles induce COX-2 expression through activation of STAT3 signaling pathway in HaCaT cells. Toxicol Vitr. 2018;52:235\u201342.","journal-title":"Toxicol Vitr"},{"key":"395_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1074\/jbc.272.1.217","volume":"272","author":"YS Bae","year":"1997","unstructured":"Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem. 1997;272:217\u201321.","journal-title":"J Biol Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0395-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:14Z","timestamp":1684616594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0395-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0395-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"29 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}